New report adds to growing evidence of iNKT cell therapy’s potential in solid tumors. NEW YORK, July (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clini ...

MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced the ...

NKGen Biotech, Inc. (OTC: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization ...

Our cells' identity is shaped by DNA tags called methylation. New tech, scDEEP-mC, maps these tags in single cells with ...

Microglia replacement therapy helps treat people with a rare genetic condition called ALSP, suggesting the approach could ...

Calidi Biotherapeutics Inc. has spent over 10 years developing a groundbreaking platform for the systemic delivery of genetic medicines that can precisely target tumors. One of the company's core ...

If measured from beginning to end, the DNA in our cells is too long to fit into the cell's nucleus, explaining why it must be ...

Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease ...

Research led by Naval Medical University's Changzheng Hospital in China reports that an off-the-shelf cell therapy built from ...

This article explores the relationship between the immune system and cancer and outlines therapeutic strategies that leverage ...

Several ASX-listed biotechs are advancing cell therapies to capture a share of a global market projected to reach US$48 ...